Public Holiday in Japan - Culture Day - Mon 4 Nov 2024 - No trading

Public Holiday in Japan - Culture Day

Monday, 4 Nov 2024

Japan Market closed, no trading for Cash Equity Market on Tokyo Stock Exchange (TSE)


Comments

Post a Comment

Popular posts from this blog

Yao Ming's 2m tall daughter Amy Yao Qinlei growing into giant at 15; overtakes wife Ye Li

Image
Yao Ming (birthday, September 12, 1980, 44) is a Chinese basketball executive, former NBA professional player and one of China's best known athletes internationally. In April 2016, Yao was elected into the Naismith Memorial Basketball Hall of Fame, alongside Shaquille O'Neal and Allen Iverson, becoming the first Chinese national to be inducted into the Hall of Fame. Yao Ming married fellow female basketball player Ye Li (43), the only lady he has ever dated on earth, on 6 Aug 2007. Husband and wife delivered baby daughter, Amy Yao Qinlei on 21 May 2010 in Houston, Texas. At 15 years old, Amy Yao Qinlei has an American citizenship is already 1.94m and still growing, currently standing around her father's shoulders, she was last spotted in Jun 2025 at the airport with her father Yao Ming. She is more introverted compared to her parents and will likely not be a professional athlete as she exhibits great intelligence and is very good in her studies. Her parents will give her th...
Read more

Yang Mi's young daughter Xiao Nuomi with Hawick Lau cute as her mother; turns down 50 mil offer for appearance

Image
Chinese actress Yang Mi's has recently been spotted bringing her daughter Xiao Nuomi (11) with ex-husband Hawick Lau to her school in Hong Kong. The doting mother has exerted great efforts to protect her daughter from the paparazzi. There was ever a variety show who offered her 50 million yuan to have her daughter featured on the show but she turned it down to protect her daughter's privacy. Besides, Yang Mi is also not short of money from her years of success in showbiz.
Read more

Daiichi Sankyo & AstraZeneca start Phase 3 Trial of DESTINY-Gastric05 for Gastric Cancer treatment

Image
DESTINY-Gastric05 Phase 3 Trial of ENHERTU® Initiated in Patients with Previously Untreated HER2 Positive Advanced Gastric Cancer Tokyo and Basking Ridge, NJ – (March 31, 2025) – The first patient has been dosed in the DESTINY-Gastric05 phase 3 trial evaluating ENHERTU® (trastuzumab deruxtecan) in combination with a fluoropyrimidine chemotherapy (5-FU or capecitabine) and Merck’s (known as MSD outside of the US and Canada) anti-PD-1 therapy KEYTRUDA® (pembrolizumab) versus trastuzumab in combination with platinum-based chemotherapy (cisplatin plus 5-FU or oxaliplatin plus capecitabine) and pembrolizumab in previously untreated patients with unresectable, locally advanced or metastatic HER2 positive (IHC 3+ or IHC 2+/ISH+) gastric or gastroesophageal junction (GEJ) cancer with PD-L1 CPS ≥1. An exploratory cohort of patients with PD-L1 CPS <1 will be randomized to either ENHERTU plus fluoropyrimidine or trastuzumab plus platinum-based chemotherapy. ENHERTU is a specifically engineered...
Read more